All In Biotech

Drug Trial Radar · NCT07936084

Clinical Trial of GenSci136 in Patients With Myasthenia Gravis

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase Ib/II Clinical Trial (Including an Open-Label Extension Phase) to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Administration of GenSci136 for Injection in Patients With Myasthenia Gravis

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

72

Planned (sponsor's estimate)

Start

Dec 2026

Primary completion

Dec 2028

Study completion Jun 2029

Sponsor

Sponsor type
Industry
First posted
Nov 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase Ib/II Clinical Trial of GenSci136 in Patients with Myasthenia Gravis

Conditions

  • Patients With MG (gMG and oMG)

Interventions

  • GenSci136 for injectionDrug

    GenSci136 for injection, administered the medication according to the requirements of the protocal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes from baseline in the incidence and severity of TEAEs/SAEs occurring within 10 weeks after the first dose and other safety measures (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG], etc.).Time frame: From time of informed consent to 10 weeks after the first dose of GenSci136
  2. Changes from baseline in the incidence and severity of TEAEs/SAEs occurring within 10 weeks after the first dose and other safety measures (physical examination, vital signs, laboratory tests, 12-lead electrocardiogram [ECG], etc.).Time frame: Approximately 26 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Huashan Hospital ,Fudan University

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.